Investment
Features
FeesSafety
Academy
More
Pluang+

Landsbankinn to release Q3 2026 financial results on October 29

Company Fundamentals
14 Oct 2026
Globe News Wire
View Source
Neutral
Landsbankinn to release Q3 2026 financial results on October 29

Landsbankinn hf. announced it will publish its financial results for the third quarter of 2026 on October 29. This update is important for investors tracking the bank's performance and financial health. The announcement also references recent covered bond auctions and exchange offerings, highlighting ongoing financial activities. Investors can expect detailed insights into the bank's earnings and operations in the upcoming report.

Landsbankinn hf.'s upcoming Q3 2026 financial results provide context for financial sector activity. For readers following financial stocks, here is Pluang's market snapshot as of Oct 14, 2026 17:11 WIB: out of 142 priced Financials-sector US stocks, 88 rose and 43 fell. Notable movers include BAC (Bank of America Corp) at USD 53.23 with a 1-day change of -1.35% and a typical hold time on Pluang of 127 days, with order activity skewed 76% Sell / 24% Buy; BMNR (BitMine Immersion Technologies Inc.) at USD 23.20 down 1.23%; and CRCL (Circle Internet Group Inc. Class A) at USD 83.23 down 1.23% but with 100% Buy order activity and a typical hold time of 2 days.

More News

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...

Others
Bullish
1 hour ago
Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...

Market News
Bullish
2 hours ago
FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...

Market News
Bullish
2 hours ago
DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...

Company Fundamentals
Neutral
2 hours ago
Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App